Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00477152
Other study ID # 1838-003
Secondary ID
Status Completed
Phase Phase 4
First received May 18, 2007
Last updated November 22, 2011
Start date August 2007
Est. completion date June 2008

Study information

Verified date November 2011
Source Baxter Healthcare Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the safety, effectiveness and ease of use of subcutaneous (SC) rehydration using HYLENEX-augmented SC infusion of fluids and electrolytes for the rehydration of pediatric patients with mild to moderate dehydration.


Description:

Pediatric patients (2 months to 10 years of age), presenting to the emergency department (ED) with mild to moderate dehydration and requiring parenteral rehydration, were treated with HYLENEX-augmented subcutaneous (SC) rehydration. An initial volume of 20 mL/kg of isotonic fluid was to be administered by continuous SC infusion over the first hour, and additional SC rehydration could be continued as clinically indicated. The preferred anatomic site for the SC infusion was the anterior thigh, unless there was an overriding preference for an alternate site.

The duration of HYLENEX-augmented SC rehydration was to be a minimum of 1 hour and a maximum of 72 hours. The investigator or designee performed a clinical assessment of the subject's hydration status at baseline and at the end of SC infusion or at discharge from the ED. Other assessments of effectiveness and safety were made directly during the rehydration period and ED stay, and by telephone on Days 3 and 7 after discharge from the ED.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date June 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender Both
Age group 2 Months to 10 Years
Eligibility Inclusion Criteria:

- Child, 2 months to 10 years of age

- Body weight less than 42 kg

- Presenting at emergency department with mild to moderate dehydration (Gorelick dehydration classification: presence of 1 to 6 [of possible 10] moderate or severe signs and symptoms) requiring parenteral rehydration

Exclusion Criteria:

- In shock or life-threatening situation (other than dehydration)

- Severe dehydration

- Requires intravenous (IV) therapy for another indication

- Indwelling IV catheter (excepting one intended strictly for clinical laboratory sample collection)

- Already received rehydration therapy IV within prior 48 hours or substantial oral fluid immediately before enrollment

- Condition precluding subcutaneous injection or infusion site evaluation in anterior thigh or other elected infusion site

- Reason for hospital admission or extended emergency department stay other than dehydration

- Known hypersensitivity to hyaluronidase or another ingredient in HYLENEX

- Hyponatremia or hypernatremia

- Hypokalemia

- Medical condition likely to interfere with ability to fully complete study or have protocol-specified assessments

- Medical history, screening examination finding or historical clinical laboratory result precluding safe participation in study or which might adversely effect interpretation of study results

- Participated in study of any investigational drug or device within 30 days prior to this study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
hyaluronidase (human recombinant)/rehydration fluid
Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Baxter Healthcare Corporation Halozyme Therapeutics, PPD

References & Publications (2)

Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, Smith SR, Reinhardt N, Hahn B, Harb G; INcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration Study Collaborative Research Group. Recombinant human hyaluronidase-enabled subcu — View Citation

Gorelick MH, Shaw KN, Murphy KO. Validity and reliability of clinical signs in the diagnosis of dehydration in children. Pediatrics. 1997 May;99(5):E6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary HYLENEX-facilitated Subcutaneous (SC) Rehydration Success Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), and discharged to home At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr) No
Primary Modified HYLENEX-facilitated Subcutaneous (SC) Rehydration Success Successfully rehydrated (as medically judged by treating physician) without rescue therapy (ie, without receiving fluids via an alternate route), regardless of emergency department discharge destination At emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr) No
Secondary Number of Attempts Needed to Successfully Place Subcutaneous (SC) Catheter At end of placement of SC catheter No
Secondary Post-treatment Gorelick Dehydration Score Score indicates the number of moderate-to-severe signs/symptoms of dehydration, based on assessment of each of the following 10 patient parameters: general condition, quality of radial pulse, quality of respiration, skin elasticity, eyes, tears, mucous membranes, urine output, heart rate and fingertip capillary refill time. Minimum score = 0; maximum score = 10. At baseline and at either the end of subcutaneous infusion (mean duration = 5.73 ± 9.15 hr) or emergency department discharge (mean time to discharge = 7.03 ± 7.57 hr) No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04079543 - NPO and Patient Satisfaction in the Cath Lab N/A
Recruiting NCT06063655 - Effects of Two Novel Hydration Beverage Formulas on Rehydration in Adults N/A
Completed NCT05111392 - Hydration Dynamics and Influence of Beverage Composition Phase 1/Phase 2
Terminated NCT02486224 - Metabolomic Analysis of the Impacts of Hydration Status on Exercise Performance N/A
Recruiting NCT02249845 - Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children N/A
Completed NCT01285713 - IV Glucose for Dehydration Treatment Phase 2
Withdrawn NCT00691275 - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Completed NCT00370968 - Zinc-ORS in Severe and Complicated Acute Diarrhea Phase 2/Phase 3
Completed NCT04076995 - INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers N/A
Recruiting NCT05768789 - Buoy Electrolyte Study on Hydration Status of Active Men and Women N/A
Not yet recruiting NCT05428228 - Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults N/A
Completed NCT04997031 - Tap Water Intake and Perceptions in US Latinx Adults
Completed NCT04536324 - The Absorption Rate of Subcutaneous Infused Fluid
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Completed NCT04874584 - Culturally Tailored Nurse Coaching Study for Cancer Symptom Management N/A
Completed NCT02206581 - Using Hydration Monitor to Detect Changes in the Hydration Status Athletes N/A
Completed NCT02265575 - Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration Phase 2
Completed NCT01893853 - Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study) N/A
Completed NCT01503996 - Drinking Habits of Glaucoma Patients and Age Matched Controls N/A